INTRODUCTION

IgG4-related disease (IgG4-RD) is an immune-mediated inflammatory condition that is capable of affecting multiple organs. Hallmarks of IgG4-RD are dense lymphoplasmacytic infiltrations with a predominance of IgG4 plasma cells in the affected tissue, which provoke tumor-like swelling of involved organs [1]. Clinical manifestations to the intracranial of IgG4-RD are known to be in the pituitary gland or meninges [2]. There have been many reported cases of hypophysitis or pachymeningitis and their pseudotumor characteristics which might be related with IgG4-RD conditions. However, no literature can be found that IgG4-RD has any associations with intracranial tumors. We report a case of meningioma and another case of pituitary adenoma with high infiltrates of lymphocytic plasma cells as a manifestation of IgG4-RD.

CASE REPORT

Case 1

A 36-year-old male patient presented with progressive motor weakness for one year. He was afebrile and neurological examination revealed grade 4 motor weakness in his four extremities with exaggerated deep tendon reflexes. He had neither papilledema nor meningeal signs. He showed normal complete blood count, erythrocyte sedimentation rate, and serum C-reactive protein level. Brain MRI and CT demonstrated a large extra-axial tumor on the right posterior fossa destructing the occipital bone, petrous part of temporal bone, the occipital condyle and C1 vertebra (Fig. 1A and B). Cerebral angiography revealed a strong vascular supply from the right occipital, right posterior inferior cerebellar and right posterior meningeal arteries (Fig. 1C and D). The patient underwent suboccipital craniectomy with complete resection of the tumor. The intraoperative findings were consistent with a meningioma. Histopathological examination showed extensive lymphoplasmacytic infiltration together with meningothelial cell proliferation, which was confirmed by immunohistochemistry directed against epithelial membrane antigen and vimentin (Fig. 2). IgG4 immunohistochemical staining was performed using a mouse monoclonal IgG4 antibody (clone HP6025, 1:1,000 dilution; Caltag Laboratory, San Francisco, CA, USA) and a rabbit polyclonal immunoglobulin G (IgG) antibody (dilution 1:100,000; Dako, Carpinteria, CA, USA). We performed immunohistochemical staining using a VENTANA-BenchMark XT autostainer with the XT ultraView DAB Kit (Ventana Medical Systems, Oro Valley, AZ, USA).
IgG4-Related Intracranial Tumors

according to the vendor’s protocol. The numbers of IgG4-positive and IgG-positive plasma cells were counted in five high power fields (HPFs) containing the highest concentration of inflammatory cells. The average number of IgG4-positive cells was 85.4/HPF. The average percentage of IgG4/IgG-positive cells was 94.0%, which meets the diagnostic criteria of IgG4-RD.

Case 2

A 54-year old woman with history of diabetes mellitus presented with right visual field defect for one month. Sellar MRI showed an invasive tumor up to 3.3 cm in diameter at sella with right cavernous sinus invasion and optic chiasm compression (Fig. 3A). Humphrey test demonstrated impaired visual field in right temporal area. There was no definite hormone elevation or hormone deficiency in pituitary function test. The patient had no other general symptoms such as fever or myalgia, and lab results showed normal WBC count, neutrophil, or eosinophil. The patient underwent transsphenoidal surgery for tumor removal. During surgery, extensive mucosal thickening of the sphenoid sinus and thick granulation tissue was found throughout the sellar floor. After excision of hypertrophied dura, hard and partially calcified mass was identified. Intrasellar part of the tumor was completely removed, however, a part of suprasellar tumor and cavernous sinus-invading tumor was remained (Fig. 3B). Pathological report showed pituitary adenoma, but dense chronic inflammation was also found along with substantial infiltrates of plasma cells (Fig. 4). Kappa, lambda immunostain was performed to rule out plas-

Fig. 1. Preoperative radiological findings of a 36-year-old male patient (Case 1). A: MRI shows a large extra-axial tumor on the right posterior fossa. B: CT reveals extensive destruction of the occipital bone. C and D: Cerebral angiography demonstrates a strong vascular supply from the right occipital artery, right posterior inferior cerebellar artery, and right posterior meningeal artery.
ma cell neoplasm, but no monoclonality was found. IgG4 immunohistochemistry showed abundant positive IgG4 plasma cells with 24.8% of IgG4/IgG-positive cells, which was lower than the diagnostic cutoff of IgG4-RD. However, based on the laboratory test that showed no abnormal findings but elevation of serum IgG4 (2,750 mg/L), we made a diagnosis of possible IgG4-RD [3]. Patient did not experience any new neurological symptoms after surgery and her visual field defect did not improve. The postoperative course was uneventful until she was discharged 9 days after the surgery. She was asymptomatic throughout regular outpatient clinic’s follow-up. However, she visited our clinic’s emergency room two months after discharge, presenting with symptoms of diplopia, ptosis and eyeball pain of the left eye which developed over a week. Her left pupil was anisocorically dilated up to 5 mm upon physical examination, and brain MRI showed newly developed bulging contour in the left cavernous sinus with adjacent profound dural thickening (Fig. 3C). As MRI finding was more indicative of inflammatory pseudotumor rather than true tumor, steroid medication was immediately started. The patient showed dramatic response to steroid treatment and her neurological symptoms greatly improved. After discharge, the patient was treated with oral steroid and immunosuppressant such as azathioprine henceforth. Follow-up MRI showed decreased extent of cavernous sinus infiltration (Fig. 3D). The patient underwent proton beam therapy for the remnant pituitary adenoma. Thereafter, she has experienced several times of flare-up of IgG4-RD which was medically well controlled. Other systemic lesions such as tubular cystic lesions in the pancreatic head and diffuse bronchial wall thickening with peribronchial infiltrations in both lungs were identified by systemic diagnostic workup, however, they have been simply followed up without pathological confirmation.

**DISCUSSION**

IgG4-RD is a chronic immune-mediated fibro-inflammatory condition with systemic infiltration of multiple organs. The pathologic hallmarks of IgG4-RD are dense lymphoplasmacytic infiltrations with a predominance of IgG4 plasma cells in the affected tissue with storiform fibrosis and obliterative phlebitis [1]. The number of IgG4-positive plasma cells per HPF ranging from minimum of 30 to 50 is regarded as a sufficient criterion for the diagnosis of IgG4-RD [4]. Elevated levels of serum IgG4 is frequent in the acute phase up to 51%–70% [5], and patients usually have a good recovery after being treated with systemic glucocorticosteroid. Any organs can be involved, but the most commonly involved organs are the pancreas, kidneys, orbital adnexal structures, salivary glands, and retroperitoneum [6]. Due to its specific histopathological features and tumor-like swelling of involved organs, IgG4-RD affected patients are often misdiagnosed as having a malignancy since the lesions can mimic tumors, infections, or immune-mediated disease [7].
Their intracranial presentation is relatively rare, although various manifestations are recognized. There are published descriptions of hypertrophic pachymeningitis, inflammatory lesions of the pituitary gland, inflammatory orbital pseudotumor, pterygopalatine fossa, and cranial nerve involvement in IgG4-RD [8]. Among them, hypertrophic pachymeningitis and hypophysitis are the most frequent manifestations [2]. The first report of intracranial involvement by IgG4-RD occurred in the context of hypophysitis [9]. Since then, hypertrophic pachymeningitis has also been recognized to occur as part of the IgG4-RD spectrum, and IgG4-RD may account for a substantial percentage of cases previously regarded as idiopathic [10].

The pathogenesis of IgG4-RD is still under debate, yet there is growing evidence that it has an autoimmune basis, with important roles for both B and T cells, especially CD4+ and T-follicular helper cells. CD4+ T cells, the most abundant cells within affected tissues, are dispersed throughout IgG4-RD lesions [11]. These cytotoxic T cells make products such as granzyme B, perforin, IL-1, transforming growth factor-beta, and interferon-gamma that are potentially important mediators of the fibrosis which is a dominant part of histopathology in IgG4-RD [11]. A T-follicular helper cell response that is separate from the CD4+ cytotoxic T lymphocytes is likely to be responsible for the development of germinal centers within lymph nodes (and involved organs) and the production of cytokines that drive the IgG4 class-switch, culminating in the creation of IgG4-secreting plasmablasts and long-lived plasma cells [12]. Taken together, it is suggested that CD4+ cytotoxic T cells play a central role in the disease and that they are sus-
tained by continuous antigen presentation by cells of the B lymphocyte lineage, including but not limited to plasmablasts [11]. Recent consensus is that the IgG4 antibodies in this disease are not pathogenic themselves, but rather represent an epiphenomenon, possibly having an anti-inflammatory role.

As discussed earlier, because IgG4-RD’s extensive infiltration tends to form a mass-like lesion, it is often confused with neoplasms. Despite its mass-forming characteristics, the specific histopathologic features of IgG4-RD are distinct from that of neoplasms. However, there have been increasing studies that reported a spectrum of malignancies occurring in association with IgG4-RD, including solid tumors located in the lung, pancreas, gastrointestinal tract, and prostate, as well as lymphoma [13-17]. Tang et al. [18] reported in a cohort study that IgG4-RD patients have a 2.78-fold increased risk of having malignancy. The relationships between these two diseases remain unclear and are the subject of on-going research.

Although the mechanism underlying the co-occurrence of IgG4-RD and malignancies has not been fully determined to date, there have been numerous suggestive hypothesis. It is thought to be established that long-standing chronic inflammation plays a critical role in the development of cancer through the process of inflammation-associated carcinogenesis [19]. It could be because IgG4-RD causes sustained inflammation that may induce preferable cancerous microenvironments. Some suggests that elevated IgG4 and extensive lymphoplasmacytic inflammation shown in IgG4-RD might be an evoked response caused by antigenicity of initial cancer [14].

Other than the relationship between the malignancies and IgG4-RD, it is noteworthy that various kinds of malignancies show positive correlation with elevated IgG4 itself. IgG4 responses have also been reported in different cancers such as melanoma [20-22], extrahepatic cholangiocarcinoma [23], pancreatic cancer [24], and glioblastoma [25]. IgG4 is usually the least-represented IgG subclass in human serum, comprising less than 4% of the total IgG. High IgG4 levels usually occur following repeated or chronic exposure to an antigen, and are associated with inflammation in a range of chronic pathological conditions [26]. Elevated levels of IgG4 are also associated with immune tolerance under conditions of chronic exposure to a specific antigen. IgG4 was found to positively correlate with regulatory T-cells and to negatively correlate with cytotoxic T lymphocytes, supporting its involvement to immune tolerance [27]. If tumor lesions are thought of as pathological conditions which resemble chronic inflammation, IgG4 elevations may be a response triggered by antigenicity in tumor microenvironment [28]. Because there is yet a lack of evidence for tumor-associated IgG4 antibodies, it seems that IgG4 elevation in several types of malignancies may be a nonspecific secondary response for immune tolerance, rather than a specific response for tumor-associated antigen. Crescioli et al. [28] inferred that additional research should be required to ascertain the tumor reactivity and antigen specificity of tumor-associated IgG4 in patients with cancer.

Fig. 4. Pathological findings of a 54-year-old female patient (Case 2). A: Low power (H&E, ×12) shows a portion of pituitary adenoma (left lower) and dura with inflammation (right upper). B: High power view (H&E, ×100) shows a classic histological findings of pituitary adenoma C: Dura with dense inflammation (H&E, ×40) is noted. D: High power view (H&E, ×200) shows dense inflammatory cell infiltrates with many plasma cells. E and F: The IgG4 positive plasma cells/IgG positive cells ratio was 24.8% based on IgG (E, ×200) and IgG4 (F, ×200) staining.
IgG4-Related Intracranial Tumors

There yet has been no literature that reported the co-existence or sequential occurrence of IgG4-RD with true intracranial tumors, nor any that described pathologically confirmed IgG4-positive cells within the tumor. We hereby report two cases with a meningoima and a pituitary adenoma strongly associated with IgG4-related condition. Interestingly, their origins of tumors; meninges and the pituitary gland, are the most common intracranial sites that IgG4-RD infiltrates. Because both cases are benign tumors, their pathogenesis may not necessarily depict that of other IgG4-related malignancies as described above. According to recent literature, systemic serum IgG4 elevation in IgG4-RD or some types of malignancies seem to be a secondary epiphenomenon rather than IgG4 antibodies being pathogenic themselves [28,29]. However, it is noteworthy that in our cases the regional tumors were directly infiltrated by IgG4-positive inflammatory cells. This onsite direct interaction between inflammatory cells and tumor of their origins may be different from the hypothesized pathogenesis of various malignancies associated with IgG4-RD. Also, the benign nature of the two cases is somewhat eccentric compared to the known literature, indicating a need for different description of their pathogenesis.

We implicate from these unorthodox feature of our cases that further investigation of IgG4 immunology should be conducted. This could help us better understand the pathogenesis of IgG4-RD and lymphocytic tumor, and also lead us to a better understanding of the pathogenesis of IgG4-RD and also tumor antigenicity.

Ethics Statement

The Institutional Review Board of Severance Hospital exempted informed consent due to its retrospective nature and minimal risk for harm to the patient (2021-2673-001), and this report was conducted according to the guidelines of the Declaration of Helsinki for biomedical research.

Availability of Data and Material

Data sharing not applicable to this article as no datasets were generated or analyzed during the study.

ORCID iDs

Eui Hyun Kim  https://orcid.org/0000-0002-2523-7122
Dongkyu Kim  https://orcid.org/0000-0001-6509-1167

Author Contributions

Conceptualization: Se Hoon Kim, Eui Hyun Kim. Data curation: Dongkyu Kim, Eui Hyun Kim. Formal analysis: Eui Hyun Kim. Investigation: all authors. Methodology: Se Hoon Kim, Eui Hyun Kim. Project administration: Eui Hyun Kim. Resources: Eui Hyun Kim. Software: Se Hoon Kim, Eui Hyun Kim. Supervision: Eui Hyun Kim. Validation: Se Hoon Kim, Eui Hyun Kim. Visualization: all authors. Writing—original draft: Dongkyu Kim. Writing—review & editing: Eui Hyun Kim.

Conflicts of Interest

The authors have no potential conflicts of interest to disclose.

Funding Statement

None

REFERENCES

1. Stone JH, Khosroshahi A, Deshpande V, et al. Recommendations for the nomenclature of IgG4-related disease and its individual organ system manifestations. Arthritis Rheum 2012;64:3061-7.

2. Baptista B, Casian A, Gunawardena H, DCruz D, Rice CM. Neurological manifestations of IgG4-related disease. Curr Treat Options Neurol 2017;19:14.

3. Umehara H, Okazaki K, Masaki Y, et al. Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD). 2011. Mod Rheumatol 2012; 22:21-30.

4. Deshpande V, Zen Y, Chan JK, et al. Consensus statement on the pathology of IgG4-related disease. Mod Pathol 2012;25:1181-92.

5. Wallace ZS, Deshpande V, Matteo H, et al. IgG4-related disease: clinical and laboratory features in one hundred twentyfive patients. Arthritis Rheumatol 2015;67:2466-75.

6. Wallace ZS, Stone JH. An update on IgG4-related disease. Curr Opin Rheumatol 2015;27:83-90.

7. Stone JH, Zen Y, Deshpande V. IgG4-related disease. N Engl J Med 2012; 366:539-51.

8. Vanegas-Garcia AL, Calle-Lopez Y, Zapata CH, Alvarez-Espinal DM, Saavedra-Gonzalez YA, Arango-Viana J. Central nervous system in IgG4-related disease: case report and literature review. Rev Neurol 2016; 63:119-24.

9. Yamamoto M, Takahashi H, Ohara M, et al. A case of Mikulicz’s disease (IgG4-related plasmacytic disease) complicated by autoimmune hypophysitis. Scand J Rheumatol 2006;35:410-1.

10. Lindstrom KM, Cousar JB, Lopes MBS. IgG4-related meningeval disease: clinicopathological features and proposal for diagnostic criteria. Acta Neuropathol 2010;120:765-76.

11. Matteo H, Mahajan VS, Maehara T, et al. Clonal expansion of CD4(+) cytotoxic T lymphocytes in patients with IgG4-related disease. J Allergy Clin Immunol 2016;138:825-38.

12. Chen Y, Lin W, Yang H, et al. Ablerrant expansion and function of follicular helper T cell subsets in IgG4-related disease. Arthritis Rheuma
tol 2018;70:1853-65.

13. Ahn SS, Song JI, Park YB, Lee SW. Malignancies in Korean patients with immunoglobulin G4 related disease. Int J Rheum Dis 2017;20:1028-35.

14. Wallace ZS, Wallace CJ, Lu N, Choi HK, Stone JH. Association of IgG4-related disease with history of malignancy. Arthritis Rheumatol 2016;68: 2283-9.

15. Poo SX, Tham CSW, Smith C, et al. IgG4-related disease in a multi-ethnic community: clinical characteristics and association with malignancy. QJM 2019;112:763-9.

16. Hirano K, Tada M, Sasahira N, et al. Incidence of malignancies in patients with IgG4-related disease. Intern Med 2014;53:171-9.

17. Yamamoto M, Takahashi H, Tabeya T, et al. Risk of malignancies in IgG4-related disease. Mod Rheumatol 2012;22:414-8.

18. Tang H, Yang H, Zhang P, et al. Malignancy and IgG4-related disease: the incidence, related factors and prognosis from a prospective cohort study in China. Sci Rep 2020;10:4910.

19. Chiba T, Marusawa U, Ushijima T. Inflammation-associated cancer development in digestive organs: mechanisms and roles for genetic and epigenetic modulation. Gastroenterology 2012;143:550-63.

20. Daveau M, Pavie-Fischer J, Rivat L, et al. IgG4 subclass in malignant melanoma. J Natl Cancer Inst 1977;58:189-92.

21. Karagiannis P, Gilbert AE, Josephs DH, et al. IgG4 subclass antibodies impair antitumor immunity in melanoma. J Clin Invest 2013;123:1457-74.

22. Karagiannis P, Villanova F, Josephs DH, et al. Elevated IgG4 in patient circulation is associated with the risk of disease progression in melanoma. Oncoimmunology 2015;4:e1032492.
23. Harada K, Nakanuma Y. Cholangiocarcinoma with respect to IgG4 reaction. Int J Hepatol 2014;2014:803876.
24. Raina A, Krasinskas AM, Greer JB, et al. Serum immunoglobulin G fraction 4 levels in pancreatic cancer: elevations not associated with autoimmune pancreatitis. Arch Pathol Lab Med 2008;132:48-53.
25. Harshyne LA, Nasca BJ, Kenyon LC, Andrews DW, Hooper DC. Serum exosomes and cytokines promote a T-helper cell type 2 environment in the peripheral blood of glioblastoma patients. Neuro Oncol 2016;18:206-15.
26. Aalberse RC, Stapel SO, Schuurman J, Rispens T. Immunoglobulin G4: an odd antibody. Clin Exp Allergy 2009;39:469-77.
27. Kimura Y, Harada K, Nakanuma Y. Pathologic significance of immunoglobulin G4-positive plasma cells in extrahepatic cholangiocarcinoma. Hum Pathol 2012;43:2149-56.
28. Crescioli S, Correa I, Karagiannis P, et al. IgG4 characteristics and functions in cancer immunity. Curr Allergy Asthma Rep 2016;16:7.
29. Mahajan VS, Mattoo H, Deshpande V, Pillai SS, Stone JH. IgG4-related disease. Annu Rev Pathol 2014;9:315-47.